Lexicon Pharmaceuticals, Inc.
LXRX US
LXRX USLexicon Pharmaceuticals, Inc.
United States Composite- Business
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Company News
Lexicon Pharmaceuticals Chief Executive Lonnel Coats to Retire in July
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
Lexicon Pharmaceuticals to Host 2024 Investor Day
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Analysts Conflicted on These Healthcare Names: Xoma (XOMA) and Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA